Zurich (AWP) – A phase III clinical study comparing Astegolimab treatment to a placebo, in addition to standard maintenance treatment in people with chronic obstructive bronchopneumopathy (COPD) moderate to very severe, has not reached its main objective, indicates on Monday the Roche pharmaceutical giant.
“Phase III Arnasa study has not reached its main evaluation criterion, namely a statistically significant reduction in the AER (moderate and severe exacerbations of COPD) at 52 weeks,” said the Basel group in a press release.
The Phase IIB Phase Study Aliento, on the other hand, has reached its own, a statistically significant reduction in the annualized exacerbation rate (TEA) at 52 weeks from 15.4% when Astegolimab was administered every two weeks.
These studies, whose detailed results will be divided at a next medical meeting, have focused on a large population of old and current smokers and with history of frequent exacerbations.
“The interest of the sector for BPCO is underlined by the acquisition of Verona by Merck at $ 10 billion,” said analyst Marcel Brand of the Cantonal Bank of Zurich.
In addition, the American Medicines Agency (FDA) estimated on Friday that a clinical study on the Columvi anticancer did not provide enough evidence for approval in a specific combination. On this point, the expert of Vontobel, Stefan Schneider, does not see “easy solutions for the indication of second intention (2L)” with sales estimated at 750 million Swiss francs.
Around 10:00 am, the good rock fell 0.6% to 256.90 Swiss francs in a SMI also in the red at 0.20%.
IB/al